⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Bleomycin-Induced Scleroderma | Accelerate Your Fibrosis Research

Home/Models/Bleomycin-Induced Scleroderma

Bleomycin-Induced Scleroderma

chemicalfibrosisskin

Species

Mouse

Duration

4

Protocol ID

M-cG9zdDoyMzE=

Model Overview

Models systemic sclerosis (SSc) with skin thickening and lung fibrosis.

Methodology

Key Endpoints

Dermal thickness
Hydroxyproline content
Alpha-SMA expression

Relevant Publications

Autoantibody landscape and functional role of anti-C-C motif chemokine receptor 8 autoantibodies in systemic sclerosis: post-hoc analysis of a B-cell depletion trial.

Matsuda KM, Chen YY, Ebata S et al.

Nat Commun2025 Dec 4

Vimentin immunization induces TH2/TH17 cell activation and autoantibody production in a novel mouse model of bleomycin induced systemic sclerosis.

Lee CR, Lee SY, Moon J et al.

Front Immunol2025

A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects.

Lee AR, Jeon SB, Kwak HW et al.

Front Immunol2025

Concentrated Micronized Fat Ameliorates Skin Fibrosis in Bleomycin-Induced Murine Model and Enhances Fat Graft Survival.

Ma X, Dong M, Yin N et al.

Aesthetic Plast Surg2025 Oct 8

The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis.

Davan-Wetton CS, Khodeneva N, Denton CP et al.

Arthritis Res Ther2025 Sep 30

View more on PubMed